Our results highlight the importance of TKIs in combination with anti-HER2 mAbs, such as inetetamab, in treating patients with HER2-overexpressing gastric cancers or breast cancers refractory to trastuzumab and provide insight into the design of new combination therapies with anti-HER2 mAbs. Here, ERBB2 is linked to breast carcinoma.